AstraZeneca China Oncology Business Restructuring to Be Implemented in 2025

AstraZeneca China’s oncology business is about to undergo a significant organizational adjustment. According to various industry sources, starting from January 1, 2025, AstraZeneca China’s oncology business will implement a new organizational structure to further enhance business focus and collaboration efficiency.

The main content of this adjustment includes the establishment of four independent and collaborative divisions within the oncology business segment: the Lung Cancer Division, the Urology, Gynecology, and Gastrointestinal Oncology Division, the Breast Cancer Division, and the Hematology Division. Additionally, the marketing and sales teams will also be reorganized under the new structure.

Along with the structural adjustments, changes in the executive team will also occur. Zhang Lingyan (currently AstraZeneca China’s Vice President and head of the Lung Cancer Division and Gastrointestinal Oncology) will be transferred to the Urology, Gynecology, and Gastrointestinal Oncology Division and will serve as AstraZeneca China’s Vice President and head of this division. The position of head of the Breast Cancer Division will be selected through internal and external recruitment, currently temporarily held by Guan Dongmei, the General Manager of AstraZeneca China’s oncology business. Additionally, other management positions will also be adjusted accordingly to support the new business layout.

The restructuring of AstraZeneca China’s oncology business can be traced back to earlier initiatives. In June of this year, AstraZeneca adjusted its oncology team, dismantling the county-level oncology teams and integrating them into the Lung Cancer Division and the Urology, Gynecology, and Female Oncology Division effective from July 1. Furthermore, in early December, AstraZeneca made role adjustments for several members of the management team in China.

In light of a series of adjustments, AstraZeneca is increasingly focusing on core tumor types such as lung cancer and breast cancer, while enhancing the importance of gastrointestinal and hematological tumors within its business landscape. These adjustments indicate that AstraZeneca is continuously optimizing resource allocation to adapt to market changes and further consolidating its position in the oncology field in China.

Strategic Significance and Market Performance of the Oncology Segment

Oncology is recognized as the most valuable therapeutic area and a key focus for multinational pharmaceutical companies. As one of AstraZeneca's core business segments, its oncology product line covers multiple fields including lung cancer, breast cancer, gastrointestinal tumors, and hematological tumors, becoming a significant pillar of the company's revenue.

According to financial report data, in the first three quarters of 2024, AstraZeneca’s global revenue reached $39.182 billion, a year-on-year increase of 19%. Among this, the oncology business contributed nearly $16 billion, a year-on-year increase of 22%, accounting for 40.8% of total revenue. In terms of sub-segments, lung cancer and breast cancer are AstraZeneca's most competitive tumor types.

In the lung cancer field, AstraZeneca boasts several blockbuster products, including Osimertinib (third-generation EGFR-TKI), Trastuzumab deruxtecan (antibody-drug conjugate, ADC), and Durvalumab (PD-L1 inhibitor). Notably, Osimertinib occupies a significant position in the EGFR inhibitor market, although it faces intense competition from domestic and international counterparts such as Amivantamab and Fumetinib.

The product pipeline in the breast cancer field also shows strong performance, with Trastuzumab deruxtecan being regarded as an innovative drug for breast cancer treatment. This drug successfully entered the medical insurance program and is currently the first and only ADC drug approved for the treatment of HER2-mutated advanced non-small cell lung cancer in China.

To continuously expand its product line, AstraZeneca relies not only on internal research but also on various methods such as collaborative development, joint research, and global licensing. For example:

• On September 5, 2024, AstraZeneca reached a clinical research cooperation agreement with Jiangsu Hailai New Medical Technology to jointly explore the application of immune checkpoint inhibitors combined with electric field therapy in biliary malignant tumors and gastrointestinal solid tumors;
• In May 2024, AstraZeneca entered into a cooperation agreement with Nona Biotech (a wholly-owned subsidiary of Hengbai Pharmaceuticals) to acquire the rights to a monoclonal antibody targeted therapy for oncology for $604 million.

AstraZeneca expects to launch over 10 blockbuster oncology products and more than 80 new indications in the Chinese market by 2030, further strengthening its competitiveness in the oncology field in China.

Multinational Pharmaceutical Companies' "Addition and Subtraction" and Strategic Considerations

In response to the complex changes in the Chinese market, many multinational pharmaceutical companies are adopting different strategies. For example, companies like Novo Nordisk and Bayer are expanding investments as a form of "addition"; Novo Nordisk is investing 4 billion yuan to expand its sterile formulation project in Tianjin, while Bayer is investing 600 million yuan to build a new supply center in Qidong, Jiangsu.

At the same time, some companies choose to "subtract" by divesting businesses. For instance, Xiehe Qilin announced the restructuring of its Asia-Pacific business, selling its Chinese subsidiary to Hong Kong Weijian Pharmaceutical Group for 720 million yuan. These adjustments reflect the strategic trade-offs that multinational pharmaceutical companies are making in the Chinese market, responding to both the Chinese policy environment and the execution needs of global strategies.

For AstraZeneca, this structural adjustment is not only a rapid response to changes in the Chinese market but also part of its global oncology strategy, aiming to solidify its leading position in the oncology field in China and globally through resource optimization and product upgrades.